Annual report
4587.TEDINET S100VITV
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardIFRS
ConsolidatedYes
Data checks21 of 22 passed
Key figures · 159
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥46.7bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥28.7bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥21.1bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥8.1bn | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥6.6bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥92.8bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥69.5bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥60.1bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥63.9bn | at 2022-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥27.0bn | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥26.1bn | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥36.0bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥29.1bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31d | Cons. | Equity IFRS |
| Net assets / equity | ¥30.5bn | at 2022-12-31d | Cons. | Net assets (5-year summary) |
| Equity (owners) | ¥56.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥40.3bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥25.4bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥21.3bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥48.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥23.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥12.4bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥350m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥8.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥1.3bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.3bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥264m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥21.0bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥115.85 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.41 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥51.13 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥115.68 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.38 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥437.63 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥311.16 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥234.8 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥246.63 | at 2022-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥195.1 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 61.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 58.1% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.5% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.4% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 30.9% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.4% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 24.4% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 26.3% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 621 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 603 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 569 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 141 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 128 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥31.3bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥12.7bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥15.4bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥11.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥21.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥6.4bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥20.5bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.4bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.8bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥29.8bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥7.0bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥21.1bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥5.8bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥4.3bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥89.7bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥68.2bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥55.2bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.6bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.3bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥34.1bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥27.6bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥55.6bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥40.6bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥29.4bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥25.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥21.2bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥44.6bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥16.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥237m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥162.6 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.85 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.11 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.98 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.4 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.26 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥428.73 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥312.89 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.48 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.39 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.0% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.5% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.2% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 43.8% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.6% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 130,010,400 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,910,400 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 157 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 153 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 155 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 141 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 128 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥741m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥741m |
| Drug Discovery And Development Businessreportable segment | employees | at 2024-12-31 | 157 pure |
| Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥31.3bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥31.3bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥21.0bn |
| Radiopharmaceuticals Businessreportable segment | employees | at 2024-12-31 | 464 pure |
| Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥16.1bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥15.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥741m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥247m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥47.4bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥46.7bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥741m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥21.2bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥87m |
| Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥12.7bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥12.7bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥6.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥16.1bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥16.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥87m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥475m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥28.8bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥28.7bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥87m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,490
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)猪 俣 雅 弘 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)中 島 悠 史 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)放射性医薬品事業に配分されたのれんの減損損失の認識の要否に関する判断の妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)連結財務諸表注記「３．重要な会計方針（10）非金融資産の減損」及び「13．のれん及び無形資産」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)Novartis Pharma AG に対する契約一時金に係る収益認識の適切性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)連結財務諸表注記「５．セグメント情報（５）主要な顧客に関する情報」 | |
| Reference2 kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)連結財務諸表注記「３．重要な会計方針（14）収益」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)猪 俣 雅 弘 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)中 島 悠 史 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)Novartis Pharma AG に対する契約一時金に係る収益認識の適切性 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（重要な会計方針）４.収益及び費用の計上基準」 | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior4YearDuration | － | JPY |
| Revenue IFRS (5-year summary) | Prior3YearDuration | 9422214000 | JPY |
| Revenue IFRS (5-year summary) | Prior2YearDuration | 26852430000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 28712194000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYearDuration | 46676523000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior4YearDuration | － | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior3YearDuration | 3803764000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior2YearDuration | 6653325000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 4353469000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYearDuration | 20888805000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior4YearDuration | － | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior3YearDuration | 2573232000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior2YearDuration | 7554358000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 3035832000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | CurrentYearDuration | 15014922000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior4YearDuration | － | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior3YearDuration | 3546177000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior2YearDuration | 6606348000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 8760519000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | CurrentYearDuration | 16216367000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | mismatch |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |